Russell Investments Group Ltd. Raises Stake in Astrazeneca PLC (AZN)

Russell Investments Group Ltd. grew its position in Astrazeneca PLC (NYSE:AZN) by 198.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,856,140 shares of the company’s stock after buying an additional 1,235,239 shares during the quarter. Russell Investments Group Ltd. owned 0.07% of Astrazeneca PLC worth $62,883,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Meeder Asset Management Inc. purchased a new position in Astrazeneca PLC in the second quarter valued at $105,000. WFG Advisors LP boosted its holdings in Astrazeneca PLC by 36.0% in the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after purchasing an additional 984 shares during the period. Bronfman E.L. Rothschild L.P. boosted its holdings in Astrazeneca PLC by 71.2% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after purchasing an additional 1,769 shares during the period. Westport Asset Management Inc. purchased a new position in Astrazeneca PLC in the second quarter valued at $170,000. Finally, First Interstate Bank boosted its holdings in Astrazeneca PLC by 10.3% in the second quarter. First Interstate Bank now owns 5,127 shares of the company’s stock valued at $175,000 after purchasing an additional 480 shares during the period. 14.16% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Russell Investments Group Ltd. Raises Stake in Astrazeneca PLC (AZN)” was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://transcriptdaily.com/2017/11/18/russell-investments-group-ltd-raises-stake-in-astrazeneca-plc-azn.html.

AZN has been the subject of a number of recent research reports. BidaskClub lowered Astrazeneca PLC from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Leerink Swann lowered Astrazeneca PLC from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $36.00 to $31.00 in a report on Thursday, July 27th. Cowen and Company reiterated a “hold” rating and issued a $34.00 target price on shares of Astrazeneca PLC in a report on Friday, July 28th. Morgan Stanley lowered Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, July 28th. Finally, Pareto Securities upgraded Astrazeneca PLC from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $34.20.

Astrazeneca PLC (NYSE AZN) traded down $0.06 on Friday, hitting $33.46. The stock had a trading volume of 2,467,623 shares, compared to its average volume of 4,805,815. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. Astrazeneca PLC has a twelve month low of $25.55 and a twelve month high of $35.60. The firm has a market capitalization of $83,500.00, a PE ratio of 7.94, a P/E/G ratio of 3.14 and a beta of 0.79.

Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.55. The business had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $6 billion. Astrazeneca PLC had a return on equity of 34.02% and a net margin of 15.90%. The business’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.32 earnings per share. equities research analysts forecast that Astrazeneca PLC will post 1.93 earnings per share for the current fiscal year.

Astrazeneca PLC Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply